Literature DB >> 1854182

Effect of low-level and intermittent minocycline therapy on the growth of Mycobacterium leprae in mice.

R H Gelber1, P Siu, M Tsang, P Alley, L P Murray.   

Abstract

We evaluated the minimal concentrations of minocycline in the diet and in serum required to inhibit the growth of seven Mycobacterium leprae isolates in mice. Minocycline concentrations of 0.01 and 0.04% in the diet, which resulted in levels in serum of less than or equal to 0.17 and 0.51 microgram/ml, respectively, were consistently and completely inhibitory. Even 0.004% dietary minocycline (levels in serum, less than or equal to 0.08 microgram/ml) partially inhibited five of these strains, while 0.001% minocycline was consistently inactive. For five of these isolates, minocycline at a concentration of 0.04% in the diet given 3 days (Monday, Wednesday, Friday) and 1 day weekly completely inhibited the growth of M. leprae, and minocycline given even 1 day monthly was partially inhibitory for three of these five M. leprae isolates.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1854182      PMCID: PMC245143          DOI: 10.1128/AAC.35.5.992

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

Review 1.  Progress in the chemotherapy of leprosy: status, issues and prospects.

Authors:  R H Gelber
Journal:  Prog Drug Res       Date:  1990

2.  Effectiveness of pefloxacin in the treatment of lepromatous leprosy.

Authors:  L N'Deli; C C Guelpa-Lauras; E G Perani; J H Grosset
Journal:  Int J Lepr Other Mycobact Dis       Date:  1990-03

Review 3.  The need for new drugs in the treatment and control of leprosy.

Authors:  R J Baker
Journal:  Int J Lepr Other Mycobact Dis       Date:  1990-03

4.  Activity of minocycline in Mycobacterium leprae-infected mice.

Authors:  R H Gelber
Journal:  J Infect Dis       Date:  1987-07       Impact factor: 5.226

5.  Pharmacokinetic studies on minocycline in man.

Authors:  H Macdonald; R G Kelly; E S Allen; J F Noble; L A Kanegis
Journal:  Clin Pharmacol Ther       Date:  1973 Sep-Oct       Impact factor: 6.875

6.  A method for counting acid-fast bacteria.

Authors:  C C Shepard; D H McRae
Journal:  Int J Lepr Other Mycobact Dis       Date:  1968 Jan-Mar

7.  Activity of ofloxacin against Mycobacterium leprae in the mouse.

Authors:  J H Grosset; C C Guelpa-Lauras; E G Perani; C Beoletto
Journal:  Int J Lepr Other Mycobact Dis       Date:  1988-06

8.  Further studies of the killing of M. leprae by aminoglycosides: reduced dosage and frequency of administration.

Authors:  R H Gelber
Journal:  Int J Lepr Other Mycobact Dis       Date:  1987-03

9.  Activities of pefloxacin and ciprofloxacin against Mycobacterium leprae in the mouse.

Authors:  C C Guelpa-Lauras; E G Perani; A M Giroir; J H Grosset
Journal:  Int J Lepr Other Mycobact Dis       Date:  1987-03

10.  Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans.

Authors:  G Montay; Y Goueffon; F Roquet
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

View more
  4 in total

1.  Another view of the therapy of leprosy.

Authors:  R H Gelber
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

2.  A clinical trial of minocycline in lepromatous leprosy.

Authors:  R H Gelber; K Fukuda; S Byrd; L P Murray; P Siu; M Tsang; T H Rea
Journal:  BMJ       Date:  1992-01-11

3.  Activities of various quinolone antibiotics against Mycobacterium leprae in infected mice.

Authors:  R H Gelber; A Iranmanesh; L Murray; P Siu; M Tsang
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

Review 4.  Chemotherapy of lepromatous leprosy: recent developments and prospects for the future.

Authors:  R H Gelber
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-11       Impact factor: 3.267

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.